Adverum Biotechnologies (ADVM), a clinical-stage gene therapy company, discovers and develops novel medicines for patients suffering from rare and ocular diseases.
ADVM's pipeline includes product candidates, which are used for the treatment of wet age-related macular degeneration (wAMD), alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. Its lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development for wAMD diseases; and ADVM-043 for the treatment of A1AT. ADVM is also developing ADVM-053 to treat hereditary angioedema; and other product candidates that comprise ocular therapeutics, including AVA-311 for the treatment of juvenile X-linked retinoschisis.
It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases.
The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
March 27, 2024
RegMed Investors (RMi) Closing Bell: The anxiousness of the session was abrogated with a risk appetite satisfied
March 27, 2024
RegMed Investors’ (RMi) pre-open: climbing a wall of worry
March 26, 2024
RegMed Investors (RMi) Closing Bell: a negative sector close
March 26, 2024
RegMed Investors’ (RMi) pre-open: get some or none
March 25, 2024
RegMed Investors (RMi) Closing Bell: twists and turns as Monday closes barely positive and a coming end of March and Q1/24
March 25, 2024
RegMed Investors’ (RMi) pre-open: end of March and Q1/24 this week
March 22, 2024
RegMed Investors (RMi) Closing Bell: A question had been asked, are there legs to the sector?
March 22, 2024
RegMed Investors’ (RMi) pre-open: Buy or fly, trade or fade?
March 21, 2024
RegMed Investors (RMi) Closing Bell: The cell and gene therapy sector faltered
35 companies, 1 interpreter!
Insight, foresight and recommendation
Adverum Biotechnologies (ADVM - January '18 opened at $3.65 rolled up to $7.70 on February '18. After a $69 M offering of 10.22 M shares priced at $6.75 financing ... it's all about milestones and waiting for the news of catalysts.
hold
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors